Semaglutide Childhood Obesity Trial Meets Primary Endpoint as Novo Nordisk’s STEP Young Study Shows 40.4% of Children No Longer Classified as Having Obesity
Novo Nordisk’s phase 3 STEP Young trial found that 40.4% of children aged 6 to under 12 treated with once-weekly semaglutide were no longer classified as having obesity after 68 weeks, versus none on placebo — a first efficacy readout for semaglutide in this young age group.
